<DOC>
	<DOCNO>NCT03034512</DOCNO>
	<brief_summary>This natural history study Alpers Huttenlocher Syndrome . Patients follow time assess clinical symptom purpose expand knowledge disorder medical community .</brief_summary>
	<brief_title>Alpers Huttenlocher Natural History Study</brief_title>
	<detailed_description>The study team conduct outpatient visit medical center 6 month basis , patient able . The patient caregiver complete medical symptom questionnaire .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diffuse Cerebral Sclerosis Schilder</mesh_term>
	<criteria>All individual age confirm Alpers Huttenlocher Syndrome ( AHS ) sibling confirm AHS patient eligible participate . AHS require presence polymerase gamma 1 ( POLG ) pathological mutation , either homozygous compound heterozygote mutation , presence epilepsy either , developmental regression hepatopathy . If POLG mutation demonstrate , AHS require presence refractory seizure , developmental regression , hepatopathy well two clinical laboratory finding include elevate cerebrospinal fluid ( CSF ) protein , neuroimaging show lactate peak , reduce Nacetyl aspartate hyperintensities T2/FLAIR thalamus posterior head region , optic atrophy/cortical blindness , quantitative mtDNA reduction ( &gt; 30 % ) muscle and/or liver , nonspecific electron transport chain ( ETC ) enzyme deficiency . All patient must agree participate North American Mitochondrial Disease Consortium ( NAMDC ) Clinical Registry Patient confirm AHS sibling patient confirm AHS Not willing participate NAMDC clinical Registry</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>